Starton Therapeutics Patents – Insights & Stats (Updated 2023)

Starton Therapeutics has a total of 44 patents globally, out of which 1 has been granted. Of these 44 patents, more than 84% patents are active. The United States of America is where Starton Therapeutics has filed the maximum number of patents, followed by Australia and Canada. Parallelly, United States of America seems to be the main focused R&D centre and also is the origin country of Starton Therapeutics.

Starton Therapeutics was founded in 2017. Starton Therapeutics is a biotechnology business aiming to using patented continuous delivery technology to transform standard of care medicines so that cancer patients can get therapy continuously and live longer, better lives.

Do read about some of the most popular patents of Starton Therapeutics which have been covered by us in this article and also you can find Starton Therapeutics patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Starton Therapeutics patent portfolio.

How many patents does Starton Therapeutics have?

Starton Therapeutics has a total of 44 patents globally. These patents belong to 7 unique patent families. Out of 44 patents, 37 patents are active.

How Many Patents did Starton Therapeutics File Every Year?

Starton Therapeutics Patent Filing Trend

Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.

Year of Patents Filing or GrantStarton Therapeutics Applications FiledStarton Therapeutics Patents Granted
20232
202212
2021151
202012
20193

How many Starton Therapeutics patents are Alive/Dead?

Worldwide Patents

Starton Therapeutics Patent Portfolio

How Many Patents did Starton Therapeutics File in Different Countries?

Starton Therapeutics Worldwide Patent Filing

Countries in which Starton Therapeutics Filed Patents

CountryPatent
United States Of America9
Australia6
Canada6
Mexico5
Europe5
China4
Hong Kong (S.A.R.)1

Where are Research Centers of Starton Therapeutics Patents Located?

The Research Centers of StartonTherapeutics Patents is the United States of America.

10 Best Starton Therapeutics Patents

US7467202B2 is the most popular patent in the Starton Therapeutics portfolio and it has received 2 citations.

Below is the list of 10 most cited patents of Starton Therapeutics:

Publication NumberCitation Count
US11197852B22
CN114901287A2
WO2020219470A12
WO2020131915A12
US20220395468A11
US20220218687A11
US20220040194A11
US20210244679A11
WO2022066987A11
WO2021146309A11

What Percentage of Starton Therapeutics US Patent Applications Were Granted?

Starton Therapeutics (Excluding its subsidiaries) has filed 9 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 6 have been granted leading to a grant rate of 100%.

Below are the key stats of Starton Therapeutics patent prosecution at the USPTO.

Which Law Firms Filed Most US Patents for Starton Therapeutics?

Law FirmTotal ApplicationsSuccess Rate
Dority & Manning PA6100%
Potomac Law Group Pllc30%

List of Starton Therapeutics patents

Starton Therapeutics PatentsTitle
US11197852B2Continuous Delivery Of Lenalidomide And Other Immunomodulatory Agents
US20220395468A1Transdermal Drug Delivery Systems For Administration Of A Therapeutically Effective Amount Of Lenalidomide And Other Immunomodulatory Agents
US20220218687A1Stable Solutions Of Immunomodulatory Imide Compounds For Parenteral Use
US20220054473A1Continuous Delivery Of Lenalidomide And Other Immunomodulatory Agents
US20220040194A1Use Of Olanzapine For Treatment Of Parp-Inhibitor-Induced Nausea
US20210244679A1Treatment Of Vomiting And Nausea With Minimum Dose Of Olanzapine
US20210236417A1Transdermal Delivery Of Dronabinol
US20210220325A1Transdermal Delivery Of Dronabinol
US20210100737A1Transdermal Delivery Of Dronabinol
EP4251131A1Stable Solutions Of Immunomodulatory Imide Compounds For Parenteral Use
EP4216959A1Treatment Of Vomiting And Nausea With Minimum Dose Of Olanzapine
EP4090333A1Treatment Of Vomiting And Nausea With Minimum Dose Of Olanzapine
EP4037663A1Transdermal Delivery Of Dronabinol
EP3958866A1Continuous Delivery Of Lenalidomide And Other Immunomodulatory Agents
CN116209428ATreatment Of Vomiting And Nausea With Minimum Doses Of Olanzapine
CN114901287ATreatment Of Vomiting And Nausea With Minimum Doses Of Olanzapine
CN114650809ATransdermal Delivery Of Drocannabinol
CN113747896AContinuous Delivery Of Lenalidomide And Other Immunomodulatory Agents
WO2022260940A1Transdermal Drug Delivery Systems For Administration Of A Therapeutically Effective Amount Of Lenalidomide And Other Immunomodulatory Agents
CA3215676A1Transdermal Drug Delivery Systems For Administration Of A Therapeutically Effective Amount Of Lenalidomide And Other Immunomodulatory Agents
CA3204385A1Stable Solutions Of Immunomodulatory Imide Compounds For Parenteral Use
CA3193237A1Treatment Of Vomiting And Nausea With Minimum Dose Of Olanzapine
CA3156890A1Treatment Of Vomiting And Nausea With Minimum Dose Of Olanzapine
CA3156257A1Transdermal Delivery Of Dronabinol
CA3137594A1Continuous Delivery Of Lenalidomide And Other Immunomodulatory Agents
AU2022288865A1Transdermal Drug Delivery Systems For Administration Of A Therapeutically Effective Amount Of Lenalidomide And Other Immunomodulatory Agents
AU2022206272A1Stable Solutions Of Immunomodulatory Imide Compounds For Parenteral Use
AU2021349936A1Treatment Of Vomiting And Nausea With Minimum Dose Of Olanzapine
AU2021207844A1Treatment Of Vomiting And Nausea With Minimum Dose Of Olanzapine
AU2020358869A1Transdermal Delivery Of Dronabinol
AU2020263285A1Continuous Delivery Of Lenalidomide And Other Immunomodulatory Agents
MX2023008091AStable Solutions Of Immunomodulatory Compounds For Parenteral Use
MX2023003350ATreatment For Vomiting And Nausea With A Minimal Dose Of Olanzapine
MX2022004033ATransdermal Delivery Of Dronabinol.
MX2022005624ATreatment Of Vomiting And Nausea With Minimum Dose Of Olanzapine.
HK40060778AContinuous Delivery Of Lenalidomide And Other Immunomodulatory Agents
MX2021012901AContinuous Delivery Of Lenalidomide And Other Immunomodulatory Agents.
WO2022150561A1Stable Solutions Of Immunomodulatory Imide Compounds For Parenteral Use
WO2022066987A1Treatment Of Vomiting And Nausea With Minimum Dose Of Olanzapine
WO2021146309A1Treatment Of Vomiting And Nausea With Minimum Dose Of Olanzapine
WO2021067806A1Transdermal Delivery Of Dronabinol
WO2020219470A1Continuous Delivery Of Lenalidomide And Other Immunomodulatory Agents
WO2020131915A1Use Of Olanzapine For Treatment Of Parp-Inhibitor-Induced Nausea
WO2020118091A1Ondansetron In-Adhesive Transdermal Patch

What are Starton Therapeutics key innovation segments?

What Technologies are Covered by Starton Therapeutics?

The chart below distributes patents filed by Starton Therapeutics in different countries on the basis of the technology protected in patents. It also represents the markets where Starton Therapeutics thinks it’s important to protect particular technology inventions.

R&D Focus: How has Starton Therapeutics search focus changed over the years?

EXCLUSIVE INSIGHTS COMING SOON!

Interested in knowing about the areas of innovation that are being protected by Starton Therapeutics?

Related Articles

Leave a Comment

Fill the form to get the details:

Our comprehensive report provides an in-depth look into the patent portfolio. The report includes a breakdown of the patent portfolio across various technologies, listing the patent along with brief summaries of each patent's technology.